Dr. Ibrahim O. Farah

Dr. Ibrahim O. Farah is Professor of Biology, Director of the graduate program in Biology and Director of the JSU Animal Core Facilities, College of Science, Engineering and Technology, Jackson State University. Dr. Farah graduated with a DVM (1977) and MVSc (1983) from the University of Khartoum in Sudan. He also earned an MS degree in Public health (1981) from the Royal University of Denmark and an MPH (1985) as well as a Ph.D. (1988) from the University of Minnesota, USA.

He is an academic editor, reviewer or member of the editorial board for more than 16 peer-reviewed journals including Annual Review and Research in Biology and advances in Biology and Biotechnology (Academic Editor), the International Journal of Experimental Pathology, Biomedical Sciences Instrumentation (board member), the British and Saudi Medical journals as well as panel review member for proposals submitted to DOD, DOE, EPA and the American Biological Institute (ABI). He has received many awards and honors and is past President of the Mississippi Academy of Sciences. Dr. Farah authored and co-authored more than 200 peer-reviewed publications, book chapters and presentations as well as published abstracts in various journals, meetings, conferences and symposia.

Research Interests

Core interests include: Bioactive Compounds; Medical Microbiology; Food Microbiology; Environmental Microbiology, Health and Food Safety, Molecular and Cellular Microbiology, Biomedical Sciences and biotechnology Fermentation Technology and Animal Research. The current primary research focus has been to understand/exploit the metabolic differences between cancer and normal phenotypes in many organ-associated cancers including those of the lungs, breast, liver and the prostate. These include: (1) Implementing metabolic modulations of cellular homeostatic/energetic deregulation. (2) Understanding the differential metabolic/energetic deregulation mechanisms involved in the development of obesity as a chronic entity as well as in its relation to cancer phenotypes and (3) The experimental modulation and utility of natural biotherapeutics.